AIOS

AI-native GLP-1 care provider in Europe

AIOS is building a vertically integrated AI doctor for Europe, and it has chosen GLP-1 medication as its way into the healthcare system. No other GLP-1 provider in Europe is AI-native, and over the past year AIOS grew fortyfold to reach 100,000 GLP-1 patients in the UK. The plan is to become the UK's largest provider, then repeat the approach across the ten biggest EU markets by acquiring regulated infrastructure, retooling it and scaling it fast. After that it intends to own the whole value chain: agentic patient care, autonomous prescribing, robotic dispensing and automated manufacturing of medication. The company aims to replace marginal human time with AI throughout.